research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
Search
for
Sort by
Research
540-570 / 1000+ results 
research ADT-G as a promising biomarker for peripheral hyperandrogenism in adult female acne
ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.
research The potential of regulatory T cell-based therapies for alopecia areata
Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.
research Dupliumab therapy for alopecia areata: a case series and review of the literature
Dupilumab may help treat alopecia areata without needing high IgE levels.
research Serum Interleukin 17 as a Marker for Alopecia Areata Severity: A Case-Control Study
Higher Interleukin 17A levels may indicate more severe alopecia areata.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research 772 Alopecia areata shares OX40 activation and Th1 and Th2 increases across atopic backgrounds
research Hormonal and Immunological Correlations in Alopecia Areata Patients: Focus on Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)
Alopecia areata patients have higher hormone levels, suggesting hormonal screening could help in treatment.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Serum Level of Programmed Death Ligand1 in Alopecia Areata Patients in Relation to Disease Severity
Higher levels of PD-L1 are linked to more severe hair loss in people with Alopecia Areata.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research Evaluation of Serum Ischemia Modified Albumin Level in Male with Androgenic Alopecia
Serum IMA levels don't help diagnose AGA but may indicate its severity.
research Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report
Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
research Evaluation of Serum Homocysteine, High-Sensitivity CRP, and RBC Folate in Patients with Alopecia Areata
Patients with alopecia areata have lower RBC folate levels, especially in severe cases.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Serum 25-Hydroxy Vitamin D Level in Patients with Alopecia Areata and Its Relationship with Severity of the Disease
Lower vitamin D levels are linked to more severe alopecia areata.
research Immunohistochemical and Electron Microscopic Characterization of the Cellular Infiltrate in Alopecia (Areata, Totalis, and Universalis)
research Delayed hypersensitivity reaction to intralesional triamcinolone acetonide following treatment for alopecia areata. Intradermal testing.
Intradermal testing can better detect corticosteroid allergies than patch testing.
research Imbalance of T‐helper 17 and regulatory T cells in patients with alopecia areata
People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
research selenium and systemic lupus erythematosus (SLE): A double- blind randomised controlled trial
Selenium supplements can help improve symptoms and metabolic markers in lupus patients.
research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
research “Shedding” low yield testing for telogen effluvium: A cross-sectional study of 16,381 laboratory results from newly diagnosed patients
Most lab tests for patients with Telogen effluvium, a type of hair loss, show no or mild abnormalities; only a few specific tests are useful.
research Alopecia areata exhibits cutaneous and systemic OX 40 activation across atopic backgrounds
Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.
research Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options
Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
research 34 A patient with insulin-dependent diabetes mellitus 1 year after being diagnosed with membranous glomerulonephritis
A 9-year-old girl developed type 1 diabetes and alopecia after being treated for a rare kidney disease.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease
Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.
research T H 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
IFN-γ production by CD4 T cells is crucial for causing alopecia areata.